Drugs / Mtb72F/AS02A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00730795 | Jan → Dec 2004 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mtb72F/AS02A | “The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans.” PMID 19587528 ↗ Jul 2009 |
| Modality | Vaccine | “Healthy PPD (tuberculin purified protein derivative)-negative adult volunteers, aged 18-40 years received three doses of the candidate Mtb72F/AS02A vaccine according to a 0-1-2...” PMID 19587528 ↗ Jul 2009 |